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Natural killer (NK) cells belong to innate immunity and exhibit cytolytic activity against
infectious pathogens and tumor cells. NK-cell function is finely tuned by receptors that
transduce inhibitory or activating signals, such as killer immunoglobulin-like receptors,
NK Group 2 member D (NKG2D), NKG2A/CD94, NKp46, and others, and recognize
both foreign and self-antigens expressed by NK-susceptible targets. Recent insights into
NK-cell developmental intermediates have translated into a more accurate definition of
culture conditions for the in vitro generation and propagation of human NK cells. In this
respect, interleukin (IL)-15 and IL-21 are instrumental in driving NK-cell differentiation and
maturation, and hold great promise for the design of optimal NK-cell culture protocols.
Cytokine-induced killer (CIK) cells possess phenotypic and functional hallmarks of both
T cells and NK cells. Similar to T cells, they express CD3 and are expandable in culture,
while not requiring functional priming for in vivo activity, like NK cells. CIK cells may offer
some advantages over other cell therapy products, including ease of in vitro propagation
and no need for exogenous administration of IL-2 for in vivo priming. NK cells and CIK
cells can be expanded using a variety of clinical-grade approaches, before their infusion
into patients with cancer. Herein, we discuss GMP-compliant strategies to isolate and
expand human NK and CIK cells for immunotherapy purposes, focusing on clinical trials
of adoptive transfer to patients with hematological malignancies.
Keywords: natural killer cell, cytokine-induced killer cell, interleukin-2, interleukin-15, good manufacturing
practice, leukemia, immunotherapy
Biological Features of NK, LAK, and CIK Cells
Natural killer (NK) cells comprise 5–25% of peripheral blood (PB) lymphocytes and were initially
recognized for their ability to kill cancer cells without prior sensitization. The reader is referred
to previously published papers for a thorough review of NK development and function (1–3).
Briefly, NK cells originate from bone marrow (BM) CD34+ hematopoietic stem cells and can
also be differentiated in vitro from highly immature CD34  umbilical cord blood (UCB) cells
(4). NK cells acquire function (killing or cytokine production) after encountering and recognizing
self-human leukocyte antigen (HLA) molecules during a process termed “licensing” or NK-cell
education. However, 10–20% of NK cells remain unlicensed, as they lack receptors for self-major
histocompatibility complex (MHC) and are functionally hyporesponsive. Importantly, unlicensed
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NK cells can become alloreactive upon encounter with cytokines
in a recipient environment, e.g., after adoptive transfer into
hematopoietic stem cell transplantation (HSCT) recipients.
The function of NK cells is governed by a set of germline-
encoded activating or inhibitory receptors referred to as killer
immunoglobulin-like receptors (KIRs). The extracellular domain
determines which HLA class I molecule NK cells recognize,
whereas the intracytoplasmic domain transmits either an activat-
ing or an inhibitory signal. KIRs are monomeric receptors with
either 2 (KIR2D) or 3 (KIR3D) immunoglobulin-like domains,
and are further subdivided into those with long (L) cytoplas-
mic tails (KIR2DL and KIR3DL) and short (S) cytoplasmic
tails (KIR2DS and KIR3DS) (5–7). Long-tail KIRs generate an
inhibitory signal through the recruitment of the SH2-domain-
containing tyrosine phosphatase 1 protein (SHP1) (8–11). Short-
tail KIRs possess truncated portions that transduce activating
signals via tyrosine phosphorylation of DAP12 and other pro-
teins (12–14).
Natural killer cells also express other activating receptors that
recognize “stress ligands” on virally infected or malignant cells.
For instance, NKG2D, a C-type lectin receptor that belongs
to the NK group 2 (NKG2) of receptors as member D (15),
is constitutively expressed on NK cells and recognizes MHC
class I chain-related genes A and B (MICA and MICB) (16),
as well as unique long 16 (UL16) binding protein family mem-
bers (ULBPs) (17). Other activating molecules include natural
cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46 (18,
19). It has been shown that killing of tumors of non-epithelial
origin, including leukemia cell lines, involves synergism between
NCRs and NKG2D (20). Activating KIRs, such as KIR2DS1, are
likely involved in the anti-leukemia effect of NK cells (21, 22). In
2002, investigators from Perugia demonstrated superior disease-
free survival (DFS) in patients with acute myeloid leukemia
(AML) receiving BM grafts from HLA-haploidentical donors
who expressed KIR binding to MHC class I molecules absent
in the host (i.e., KIR-ligand mismatch in the GVH direction)
(23, 24). The most notable inhibitory receptors recognize HLA
class I proteins (including groups of HLA-A, HLA-B, and HLA-
C) and differ in both their transmembrane and intracytoplasmic
domains (25–29).
Human leukocyte antigen-C is the predominant class I isotype
involved in the inhibitory and activating regulation of human
NK cells (1, 22). Individuals may have up to 15 KIR genes that
reside in a single complex on chromosome 19p13.4. KIR genes
can be divided into A or B haplotypes. The A haplotype consists
of five inhibitory KIRs and a single activating KIR, KIR2DS4. By
contrast, the B haplotype contains both inhibitory and several
activating KIRs that are further subdivided into two separate
regions, centromeric and telomeric. In the “missing self ” model
(30), donorNK cells express inhibitoryKIRs forwhichHLA class I
molecules are missing in the recipient. Donors with KIR B vs. KIR
A haplotypes improve the clinical outcome for patients with AML
by reducing the incidence of leukemia relapse and prolonging
DFS (31). The centromeric KIR B genes were dominant over the
telomeric ones, and included the genes encoding inhibitory KIRs
that are specific for the C1 and C2 epitopes of HLA-C. When
the authors examined a cohort of 1,532 T-cell-replete HSCT,
relapse protection associated with donor KIR B was enhanced in
recipients with one or twoC1-bearingHLA-C allotypes compared
with homozygous recipients. This implies that a deeper under-
standing of the interaction between donor KIRs and recipient
HLA class I will allow the selection of the “best donor” to improve
outcomes of unrelated HSCT and adoptive NK infusion for AML.
Intriguingly, KIR B haplotype donors were recently shown to con-
fer a reduced risk for relapse after haploidenticalHSCT in children
with ALL (32), an effect that is not seen in adult ALL (33). In
allogeneicHSCT, particularly fromHLA-mismatched donors, NK
cells reportedly influence clinical outcome by exerting anti-tumor
effects without inducing graft-versus-host disease (GVHD) (34).
However, NK cells reconstituting after allogeneic HSCT may be
dysfunctional, likely as a result of low IL-2 levels (35). Some groups
are attempting to improve NK-cell reconstitution followingHSCT
by depleting the graft of αβ+ T cells and CD19+ B cells, but
leaving NK progenitors untouched (36). Using this approach, very
high numbers of haploidentical NK cells and NK-like (CD56+) T
cells can be infused into patients with malignant disorders (37).
Another family of human NK receptors is composed of a
common subunit (CD94), covalently linked to a distinct chain
encoded by a C-type lectin NKG2 family gene. Among the C-
type lectin NK receptors, CD94/NKG2A is inhibitory, whereas
other heterodimers are activating receptors. CD94/NKG2A binds
the non-classical class I molecule HLA-E (38). The binding of a
unique peptide/HLA-E complex to the activating CD94/NKG2C
receptor is of higher affinity than the binding to the inhibitory
CD94/NKG2A ensuring the predominance of inhibitory signals
when the same NK cells express both activating and inhibitory
receptors recognizing HLA molecules (39).
In 1980, Rosenberg and co-workers demonstrated that incu-
bation of heterogeneous lymphocyte populations with high-dose
(800-1,000U/ml) interleukin-2 (IL-2) generates lymphokine-
activated killer (LAK) cells with prompt in vitro cytotoxicity to
syngeneic and autologous fresh tumors (40–42). NK cells were
identified as precursors of LAK cells, and LAK activity was found
to be mainly, albeit not uniquely, mediated by activated NK
cells (43, 44). LAK cells comprise CD3 CD56+ NK cells, MHC-
unrestricted cytotoxic CD3+CD56+ T cells, and CD3+CD56  T
cells. However, LAK cells had limited expansion in vitro and low
cytolytic activity in vivo. Furthermore, LAK therapy required high
doses of IL-2 in vivo and was associated with relevant toxicity.
Modifications in culture conditions, i.e., provision of agonistic
αCD3 (OKT3) monoclonal antibodies (mAbs), IL-2 and inter-
feron (IFN)-γ, translated into>1,000-fold expansion of peripheral
blood mononuclear cells (PBMCs) with potent cytokine-induced
killer (CIK) activity. CIK cells share phenotypic and functional
properties of both T cells and NK cells, as they co-express CD3
and CD56, and are rapidly expandable in culture like T cells, while
not necessitating functional priming for in vivo activity, analogous
to NK cells. Interestingly, CIK cells do not recognize target cells
through the T-cell receptor (TCR) and do not require the presence
of MHCmolecules on target cells, as suggested by the observation
that cytotoxicity is not affected by antibodymasking of the TCR or
MHC class I or class II molecules. CIK cells also express activating
NK receptors, including NKG2D, DNAX accessory molecule-1
(DNAM), and NKp30 (45, 46).
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Evidence for an in vivo activity of CIK cells derives from studies
in a murine severe combined immune deficiency (SCID)/human
lymphoma model, where co-administration of CIK cells with
B-lymphoma cells had favorable effects on mice survival, with
a 1.5–2.0-log cell kill and only marginal toxicity against nor-
mal hematopoietic precursors (47). CIK cells reportedly protect
against syngeneic and allogeneic tumors also in other experimen-
tal models, including nude mice xenografted with human cervical
carcinoma cells (48–50). CIK cells are detected in the lungs 30min
after injection, followed by distribution to other sites, such as the
liver and spleen and, by 72 h, the tumor site, where CIK cells may
remain for more than 9 days (51).
Current NK-Cell Manufacturing Practices
A direct comparison of NK manufacturing techniques is
hampered by differences in starting materials, technologies, and
manipulation strategies (52, 53). Classically, GMP-compliant
NK-cell products have been generated from PBMCs collected
by apheresis (Table 1). It has been shown that NK cells obtained
from granulocyte colony-stimulating factor (G-CSF)-mobilized
leukapheresis products have reduced functional capacity (54).
Conceivably, non-mobilized blood may be preferable over G-CSF
mobilized blood as a source of NK cells for immunotherapy trials.
A variety of cellular media have been used to culture NK cells,
including X-VIVO serum-free medium, AIM V, or stem cell
growth medium (SCGM), typically supplemented with 5–10%
human AB serum to enhance NK function. Because the limited
number of NK cells in leukapheresis products restricts clinical
applicability, in vitro methods to expand NK cells are intensely
being developed. In this respect, IL-15 promotes NK-cell prolifer-
ation and survival, and has been variably used inGMP-grade labo-
ratory protocols, as further detailed below. Alternativemethods of
expansion rely on human feeder cells, including artificial antigen
presenting cells (APCs) that are modified with costimulatory
molecules, such as CD137 ligand, and membrane-bound (mb)
IL-15 or IL-21. However, expanded NK cells undergo exhaustion,
as shown by telomere shortening and replicative senescence.
In 2001, Carlens and co-workers described a cytokine-based
technique for in vitro enrichment of human NK cells from bulk
PBMCs of healthy individuals (79). PBMCs were incubated in
SCGM containing 5% human serum and varying concentrations
of IL-2. In addition, stimulation with OKT3 at 10 ng/ml was pro-
vided during the first 5 days of the culture. Supplementation with
500U/ml IL-2 yielded amedian 193-fold cell expansion in 21 days.
Fifty-five percent of the expanded cells had a CD3 CD56+ phe-
notype, and prolongation of the culture beyond 3weeks did not
allow further NK-cell enrichment. Moreover, expansion of the
NK-cell compartment was comparable in cultures containing IL-
2 concentrations ranging from 100 to 1,000U/ml. Expanded cells
could efficiently kill the NK-susceptible K562 line. This protocol
was subsequently applied to PBMCs from patients with multi-
ple myeloma (MM), an incurable plasma cell malignancy with
a unique ability to subvert anti-tumor immune responses (80).
Following an initial non-proliferative phase of 5 days, patient-
derived NK cells expanded 1,625-fold on average after 20 days
of culture (71). NK cells from MM patients displayed increased
expression ofmultiple activating receptors, including 2B4,NKp46,
NKp44,NKp30,NKG2D, andDNAM-1, andwere efficiently cyto-
toxic to K562 cells and primary autologous MM cells, but not
to autologous CD34+ cells (71). Mobilized PBMCs from patients
with MM have also been used to expand NK cells (81). After a
7-day culture with serum-free AIM V media, IL-2 and OKT3,
polyclonal populations of cytotoxic lymphocytes were detected,
including CD4+ T cells, CD8+ T cells, CD8+CD56+ T cells,
and CD56+ NK cells. Culture bags provided a two- to threefold
expansion of immune effectors that retained their cytotoxicity
after cryopreservation and thawing.
Notably, ex vivo expansion of NK cells from PBMCs incubated
with IL-2 was also pursued under GMP-compliant conditions.
Using an automated bioreactor system, bulk PBMCs from healthy
donors and MM patients could expand 77-fold on average, and
acquired enhanced cytotoxicity that positively correlated with
the up-regulation of the NKp44 activating receptor. However,
the expanded culture contained a significant proportion of T
cells, necessitating further T-cell depletion prior to clinical use
(61). Furthermore, purified CD56+ populations were positively
selected fromPBMCs of healthy individuals using CD56magnetic
microbeads, and cultured in X-VIVO 10 medium containing
10% human AB serum and 500U/ml IL-2 10 ng/ml IL-15 for
2weeks. Appreciable proliferation occurred 5–7 days from the
start of the culture, although with remarkable donor-to-donor
variability. Expansion of CD3+CD56+ NK-like T cells was two
to three times greater than that of CD3 CD56+ NK cells and
was not affected by IL-15. Compared with the NK-92 cell line, ex
vivo expanded CD56+ cells had lower lytic activity against both
K562 and Raji target cells (66).
The natural nicotinamide adenine dinucleotide (NAD)+ pre-
cursor and NAD+-dependent enzyme inhibitor nicotinamide
(NAM) has been recently shown to induce a 60- to 80-foldNK-cell
expansion when added to feeder-free cultures containing IL-2 and
IL-15 (82). In this study, NAM also affected NK cell anti-tumor
capabilities and trafficking properties by modulating expression
of CD200R and PD1, two immune regulatory receptors that
transmit inhibitory signals upon interaction with cognate ligands
on cancer cells. In addition, NAM promoted surface expression
of L-selectin, an adhesion molecule mediating interactions with
vascular endothelium and lymph nodes.
CD3+ T-Cell Depletion with or without CD56
Enrichment
The CE-approved, partially automated Clini-MACS® instrument
from Miltenyi allows the enrichment of NK cells under GMP-
compliant conditions (58). After a single step of magnetic CD3+
T-cell depletion, PBMCs are stimulated and expanded with irradi-
ated autologous cells in the presence of OKT3 and IL-2, resulting
in a highly pure population of functional CD3 CD16+CD56+
NK cells that lack cytotoxicity against allogeneic non-tumor cells
(83) (Table 1). Immunomagnetic CD3+ T-cell depletion with
either the 2.1 or the 3.1 programs can be combined with CD56-
cell enrichment (84).WhenCD56+ cells aremagnetically isolated,
the expansion of CD3+CD56+ cells in culture may outweigh that
of CD3 CD56+ cells, since CD3+ cells are not depleted upfront
(66). Furthermore, CD56 expansion in cultures supplemented
with IL-2, either alone or in combination with IL-15, shows
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TABLE 1 | Current GMP-compliant NK-cell manufacturing methods are detailed.
Reference(s) Cells Manufacturing process Feeder cells Characteristics Purity
(55) UCB CD34 immunoselection; expansion in a
bioreactor (SCF, Flt3-L, TPO or IL-15, IL-7,
G-CSF, GM-CSF, and IL-6 from d0 to d14;
same as above +IL-2 from d14 onward)
Not used 2,100-fold expansion;
1.6–3.7109 NK cells;
undetectable T and B cells
90–95% NK cells
(56) UCB IL-15, IL-2, OKT3, and heparin, with or
without tacrolimus
Not used 1,700-fold expansion;
40106 NK cells from
1.0106 UCB cells
>70% NK cells
(57) PBMCs; LK CD3 depletion; overnight incubation
with IL-2
Not used <5106 residual T cells;
>70% viability
>18% NK cells
(58) PBMCs; LK CD3 depletion (protocol I); CD56
enrichment (protocol II); overnight
incubation with IL-2
Not used 686.7106 and 253.2106
NK cells with protocols I and
II, respectively
38% (I) and 90% NK
cells (II)
(59) PBMCs; LK CD3 depletion; CD56 enrichment; no
exposure to IL-2 or other cytokines
Not used Median of 29106 NK
cells/kg infused
0.097106/kg
contaminating B cells;
1103/kg T cells in 1
product
(60) PBMCs; LK CD3 depletion; CD56 enrichment Not used 1.1–8.8108 NK cells <0.01% T cells
(61) PBMCs; LK IL-2+ anti-OKT3 in various flasks, culture
bags, and bioreactors for 20 d
Not used 530 to 1,100-fold NK-cell
expansion
31–51% NK cells
(62) PBMCs; LK CD3/CD19/CD4/CD33 depletion;
incubation with IL-2 and IL-15 for 7–21 d
Irradiated
autologous
PBMCs
100-fold NK-cell expansion at
16 d
91% CD56+ cells
(63) NK-92 cells from a
master cell bank
IL-2 Not used 2.0–42.4109 (starting from
5107)
N.A.
(64) NK-92 cells from a
master cell bank
IL-2 for 15–17d Not used >200-fold NK-cell expansion 1.5109 cells/L
(65) PBMCs; LK CD3 depletion; CD56 enrichment;
overnight incubation with IL-2, OKT3, with
or without IL-15
Irradiated
autologous
PBMCs
62.7-fold NK-cell expansion
(66) PBMCs; LK CD56 enrichment; overnight incubation
with IL-2, with or without IL-15, for 14 d
Not used 67% NK cells
(67) PBMCs; LK CD3 depletion; IL-2 for 7 d K562–mb15–41BBL 73% NK cells with
<14% T cells
(68) Autologous
PBMCs; LK
CD3 depletion; IL-2 and OKT3 for 21 d Irradiated
autologous
PBMCs
1.88–7.61010 NK cells >93% purity
(69) Autologous
PBMCs; LK
CD3 depletion; CD56 enrichment; IL-2
for 28 d
Irradiated
EBV-TM-LCLs
>96% NK cells, with no
CD3+ T cells
(70) PBMCs; LK (1-h) CD56 selection (Clini-MACS®;
research-grade); CD3 depletion (Dyna
Beads®; research-grade); partially
automated separation procedure,
clean-room conditions (“class A in B”)
Not used 160106 NK cells (<0.01%
remaining CD3+ T cells)
98.6% purity
(71) Autologous PBMCs
from patients with MM
SCGM with IL-2 and OKT3 Not used 1,625-fold NK-cell expansion
on d20
65% NK cells
(72) PBMCs; LK CD34 selection (Clini-MACS®); culture with
research-grade SCF, Flt3-L, IL-7, and
hydrocortisone for 21 d and with
research-grade IL-15, IL-21, and
hydrocortisone for additional 21d
Not used 9.28106/kg NK cells from
2.2106/kg CD34+ cells
64% NK cells with 1%
CD3+ T cells
(73) PBMCs; LK CD3 depletion; CD56 selection Not used 12.1106/kg NK cells 0.03105 median
T-cell dose
(74) PBMCs; LK CD3 depletion; overnight IL-2 in four
procedures, IL-2 during exposure to CD3
beads in six procedures
Not used >1.0106/kg NK cells <1.0105/kg T cells
(Continued)
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TABLE 1 | Continued
Reference(s) Cells Manufacturing process Feeder cells Characteristics Purity
(75) PBMCs; LK CD3 depletion; CD56 selection Not used 5.0106/kg NK cells in 77%
of patients
93.5% purity
(76) PBMCs; LK CD3 depletion; IL-2 for 8–16 h Not used 21.0106/kg NK cells 43% purity
(77) PBMCs; LK NK-cell priming with CNDO-109 lysate
(derived from a leukemia cell line, CTV-1)
Not used <104 residual T cells
(78) PBMCs; LK CD3 depletion; 1,000U/ml IL-2 Not used Median 26% haploidentical
NK cells; three dose levels
Median viability >95%
PBMC, peripheral blood mononuclear cells; LK, leukapheresis; d, day; UCB, umbilical cord blood; SCGM, stem cell growth medium; MM, multiple myeloma.
substantial inter-donor variability. Each of the above programs
translates into differences in depletion efficiency and recovery
of NK cells, with NK purification being improved after sequen-
tial processing with the Clini-MACS T-cell depletion programs
D2.1 and D3.1. Not unexpectedly, absolute NK-cell numbers
after manipulation may correlate with the pre-harvest NK-cell
content of the PB (85), implying that donors with high NK-cell
counts are likely to provide NK-cell products with the highest
cell numbers. A clinical-scale procedure to isolate NK cells for
infusion in pediatric patients was developed under clean-room
conditions (70). One-hour leukapheresis collections fromunstim-
ulated healthy donors were used to positively select CD56+ cells
and negatively deplete T cells, ultimately leading to cell therapy
products enriched in NK cells and containing only 0.09% remain-
ing T cells. A similar procedure consisting of two rounds of CD3
depletion and one round of CD56 selection has been used to
obtain clinically applicable numbers of NK cells for immunother-
apy (86). In that study, NK cells were expanded with IL-2 for
10–14 days to achieve the desired cell dose for potential clinical
application in three children with relapsed or refractory leukemia
after haploidentical HSCT.
Natural killer cells can also be expanded with irradiated autol-
ogous feeder cells, IL-2, IL-15, and anti-CD3 antibodies. Using
these systems, NK cells acquire a CD56intCD16int phenotype and
increase an average of 117-fold in 3weeks (65). IL-2 and IL-15
mediate betterNK expansion and viability comparedwith cultures
nurtured with IL-2 only. Importantly, the number of residual con-
taminating T cells may be significantly lower after NK-cell expo-
sure to IL-2 and IL-15 compared with IL-2 alone. NK cells acti-
vated with IL-2 and IL-15 may display higher cytotoxicity against
K562 cells when kept in culture at a low effector-to-target ratio
(66). In order to selectively expand alloreactive NK cells, KIR+
cells can be isolated fromClini-MACS-purifiedCD3 CD56+NK
cells using cell sorting, and then stimulatedwith the same cytokine
cocktail (65). GMP-sorted and expanded single KIR+ cells were
cytolytic against AML blasts, an effect that was more pronounced
than that mediated by bulk NK cells in an HLA-mismatched
setting.
Interleukin-21 can offer theoretical advantages for the expan-
sion of NK cells. The temporal exposure of IL-2/IL-15-stimulated
NK cells to IL-21 determines the extent to which NK-cell pro-
liferation and function are promoted (87). Specifically, NK cells
stimulated with IL-21 during the first week of culture were
shown to have strong proliferative response and cytotoxic activ-
ity compared with control cultures. The short-term expanded
NK cells had longer telomeres than NK cells maintained with
IL-21 continuously. IL-21 has also been used in combination
with IL-15 to activate HLA-mismatched NK cells derived from
CD34+ hematopoietic progenitors with SCF, Flt3-L, IL-15, and
hydrocortisone (72).
Use of Feeder Cells
While the minimum necessary NK-cell number for therapeutic
efficacy is still controversial, the consistent generation of large
amounts of functional cells is crucial to develop clinical protocols
of adoptively transferred NK cells. Different feeder cell types
have been used to expand NK cells, including irradiated PBMCs,
EBV-transformed lymphoblastoid cell lines (EBV-LCL), gene-
modified K562 cells expressing NK cell-stimulatory molecules
such as 41BB-ligand and mbIL-15 (67). Compared with IL-2-
mediated activation, NK-cell expansion in the presence of feeder
cells may also result in increased anti-tumor cytotoxic functions,
with comparable in vivo survival (69, 88).
K562 cells were transduced with constructs encoding mbIL-15
(IL-15+CD8α) and human 41BB-ligand (both containing green
fluorescent protein). NK-cell recovery was 21.6-fold after 7 days
of culture and increased to 152-fold and 277-fold after 14 and
21 days of culture, respectively. Importantly, the median recovery
ofNK cells was comparable whenmononuclear cells frompatients
with acute leukemia were used in the co-culture. The expanded
NK cells were cytotoxic against both AML cell lines and primary
AML blasts. When compared with IL-2-stimulated NK cells, the
cytotoxicity of expanded NK cells was greater at all effector-to-
target ratios (67). In a mouse model of AML, multiple injections
of expanded NK cells vigorously suppressed leukemia growth,
with some mice achieving long-term control of the disease in the
absence of xenogeneicGVHD. Finally, amaster cell bank of K562–
mb15–41BBL cells was established following GMP guidelines.
The transduced NK cells were used to expand NK cells from
leukapheresis collections at a 1:10 NK cell-transduced K562 cell
ratio. The expansion of NK cells ranged from 33- to 141-fold after
7 days in culture. The overall yield of NK cells was higher than that
observed in small-scale experiments.
A GMP-compliant NK-expansion methodology was also
applied to patients with metastatic melanoma or renal cell carci-
noma. A 278- to 1,097-fold NK-cell expansion was obtained when
OKT3-loaded, 30-Gy-irradiated autologous PBMCs were used
as feeders in AIMV medium containing 10% human AB serum
and 600U/ml IL-2 for 21–26 days. Following adoptive transfer to
patients treated with a lymphodepleting regimen, expanded NK
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cells persisted formultiple days, likely representing themajority of
NK cells in the circulation 1week after infusion (68). Autologous
PBMCs have also been used as feeders for the expansion of NK
cells from healthy donors. Feeder cells obtained from the NK-
depleted fraction of donor leukapheresis collections were used
at a 10:1 feeder/NK-cell ratio for a GMP-compliant expansion
procedure in Baxter LifeCell culture bags containing SCGM Cell-
Gro medium, 5% human AB serum, and 200U/ml IL-2 with
or without IL-15 supplementation. This protocol was successful
in propagating cultured NK cells, which expanded 117 20-fold
after 19 days in the presence of 10 ng/ml IL-15 (65).More recently,
a similarNK-cell expansion efficiencywas reportedwhenNKcells
from healthy donors or patients with ALL in CR were co-cultured
with autologous PBMCs in CellGro SCGM medium containing
IL-2 and IL-15 (respectively, 34.9- vs. 39.5-fold average expansion
after 14 days) (89).
Allogeneic PBMCs have been used as feeder cells for large-scale
expansion of clinical-grade NK cells (62, 69). Allogeneic PBMCs
and NK cells were co-cultured in X-VIVO 20 medium containing
500U/ml IL-2 (69), or 100U/ml IL-2 and 10 ng/ml IL-15 (62).
In these studies, a similar 80- to 100-fold NK-cell expansion was
achieved in 14–15 days. In an interesting study from Kim and
colleagues, autologous PBMC feeders from cancer patients or
PBMCs from healthy donors were compared (90). Co-cultures
containing PBMCs from healthy donors could more efficiently
propagate NK cells than those containing PBMCs from cancer
patients (respectively, 300- vs. 169.4-fold average expansion after
14 days).
Pittari and colleagues described a novel technique for selec-
tion, deposition, and high-efficiency cloning of individual NK
cells displaying surface receptor repertoires of choice. Cells were
selected by FACS, deposited into U-shaped polystyrene 96-well
plates (one cell per well) containing CellGro SCGM medium
supplementedwith 10%humanAB serum andwithout exogenous
cytokines. Propagation of NK clones from single cells was driven
by trans-presentation of IL-15 by BaF/3 pre-B-lymphocytes dou-
ble transfected with human IL-15Rα and human IL-15 (BaF/3
IL-15Rα/IL-15). Additional feeder cells were EBV-BLCL (JY) and
PBMCs from three allogeneic donors (91). In this pre-clinical
design, the technique allowed for prompt propagation of NK
clones from NK-cell populations potentially involved in the con-
trol of leukemia relapse, i.e., expressing the KIR2DS1 activat-
ing receptor (22), regardless of their frequency (Figure 1). After
3weeks, propagated NK clones typically reached 0.25–4 106
cells, with an overall cloning efficiency as high as 35–40%.
The replicative potential of NK cells expanded with genetically
modified K562 cells can be further enhanced by enforcing the
expression of human telomerase reverse transcriptase (TERT)
gene (92). After stimulation with K562 cells for 1week, NK cells
were transfected with a retroviral vector containing human TERT.
At variance with the control cultures that underwent replicative
senescence after 16 population doublings, TERT-NK cells contin-
ued to expand in vitro for more than 1,000 days, if periodically
re-stimulated with K562 cells. However, NK cells accumulated
genetic changes at late time-points, including gain in genes on
chromosome 1 and losses in genes on chromosome 16, suggesting
that genetic instability may be a limiting factor in immortalization
of NK cells.
Gas-permeable cell culture devices (G-Rex) are being evaluated
for the expansion of T cells and tumor cells. In these systems, gas
exchange across the base of the culture allows increased volumes
of medium per unit area, augments the rate of cell expansion,
and decreases cell death, minimizing cell manipulation. Using
this strategy, up to 19 109 functional NK cells were produced
starting from leukapheresis products, within 8–10 days of culture
(93). The contaminating T cells mostly comprised CD8+ T cells
and could be removed by magnetic depletion. When compared
with conventional gas-permeable bags, the G-Rex yielded higher
fold expansions of NK cells, requiring no interimmanipulation or
feeding during the culture period. The NK cells were viable and
functional, even after 12months of cryopreservation.
Use of Cord Blood and Other Stem Cell Sources
to Expand NK Cells
Umbilical cord blood is an emerging source of NK cells for clinical
applications and also provides an in vitro system to analyze NK
development (4). Banked UCB units represent an ideal “off-the-
shelf ” source of NK cells for adoptive immunotherapy. Impor-
tantly, NK cells from PB and UCB differentially express cytokine
receptors, with IL-15Rα being preferentially detected onUCBNK
cells and IL-12Rβ1 and IL-18α receptors being primarily found
on PBNK cells (94, 95). The combination of IL-15 and IL-18 opti-
mally stimulates the proliferation of UCBNK cells and potentiates
the release of IFN-γ andTNF-α. The lower responsiveness ofUCB
NK cells to IL-2 observed in these studies may be the result of
lower expression of IL-2 receptors and of decreased phosphory-
lation of STAT5 as compared with PB NK cells. This implies that,
at variance with PB NK cells that are fully activated by IL-2 alone,
UCB NK cells may require additional cytokine stimuli (96). For
instance, the addition of tacrolimus and low-molecular-weight
heparin significantly enhances NK-cell expansion induced by IL-
2, IL-15, and anti-CD3 mAbs (56). Using this protocol, approxi-
mately 40 106 NK cells were obtained from 1 106 unmanip-
ulated UCB cells, in the absence of feeder cells, corresponding
to >1,000-fold expansion. Bioreactors have been used to expand
UCB-derived NK cells as well. This approach resulted into the
generation of a clinically relevant dose of NK cells with >2,000-
fold expansion, purity of >90%, high expression of activating
receptors and cytolytic activity against K562 leukemia cells (55).
It has been shown that UCB-derived NK cells actively migrate
to the BM, spleen, and liver 24 h after infusion in NOD-SCID-IL-
2Rγ-nullmice (97).NK cells were differentiated in 3–4weeks from
CD34+ hematopoietic progenitors exposed to multiple cytokines,
and were found to express CXCR4, CXCR3, and CCR6, which
likely accounted for their ability to home to BM and inflamed
tissues. A single NK-cell infusion combined with in vivo low-dose
IL-15 resulted in inhibition of leukemia growth and prolongation
of mice survival.
Finally, human embryonic stem cells (ESCs) as well as induced
pluripotent stem cells (iPSCs) are potential sources of pheno-
typically mature and functional NK cells (98). ESCs and iPSCs
were first used to produce hematopoietic progenitors with the
“spin embryonic body (EB)” method, in which defined numbers
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FIGURE 1 | Generation of NK clones from individual NK cells
with specific KIR receptor repertoires. (A) Flow cytometry
representation of NK-cell subsets defined by a combination of four
anti-KIR mAbs. In this example, subsets used for FACS-assisted
single-cell deposition express 2DS1, either alone (subset 1, red) or in
combination with at least one receptor among 2DL2, L3, and S2
(subset 2, green) or 3DL1 (subset 3, blue). The percent frequency of
NK-cell subsets is indicated. (B) Representative NK clones obtained
after 3-week in vitro propagation in the presence of IL-15
trans-presentation. E115: 2DS1pos; E78: 2DS1pos/CH-Lpos; E86:
2DS1pos/3DL1pos. For E78, specific KIR(s) can be identified by
real-time RT-qPCR.
of cells were spin-aggregated in serum-free medium. This strat-
egy removed the need for murine stromal support, and led
to hematopoietic cell development and proliferation. Spin EB-
derived cells were then tested in a feeder-free and serum-free
system containing NK-cell promoting cytokines, i.e., IL-3, IL-7,
IL-15, SCF, and Flt3-L. Within the first 2 weeks of culture, both
non-adherent CD31+ endothelial cells and CD73+ mesenchymal
stromal cells were detected. Importantly, NK cells developed in
similar numbers, phenotype, and functional characteristics as
those differentiatedwith the use ofmurine stromal cells (98). Arti-
ficial APCs engineered to express mbIL-21 additionally expanded
NK cells. As the expected requirement for NK-cell adoptive trans-
fer protocols is approximately 2 107 NK cells/kg (see below),
genetically modified APCs allow the use of a starting population
of <106 ESCs/iPSCs per patient, corresponding to a lower num-
ber of cells compared with that required for NK-cell expansion
from the PB.
Use of Genetically Engineered NK Cells
Although lentiviral (LV) vectors have been successfully used to
transduce both T cells and NK-cell lines, LV transduction of both
freshly isolated and ex vivo-expanded NK cells may be challeng-
ing. Chimeric antigen receptors (CARs) are synthetic engineered
receptors that target surface molecules in their native conforma-
tion, independent of MHC and of antigen processing by the target
cells (99). The generations of CARs are typically classified based
on the intracellular signaling domains, with first-generationCARs
including only CD3ζ, second-generationCARs including one sin-
gle costimulatory domain and third-generation CARs including
two costimulatory domains, such as CD28 and 41BB.
Natural killer cells can be transduced with mRNA encoding for
anti-CD19 CARs. The expression of a receptor containing CD3ζ
and 41BB signaling molecules (anti-CD19-BB-ζ) was induced
in human NK cells with a clinical-grade electroporator. The
cytotoxicity of the transfected NK cells was evaluated both in vitro
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and in a mouse model of leukemia. Receptor expression was
already detectable 6 h after electroporation, reaching maximum
levels at 24–48 h. Toxicity against CD19-expressing targets was
specifically observed at 96 h. Median anti-CD19-BB-ζ expression
24 h after electroporation was 40.3 and 61.3% in freshly purified
and in expanded NK cells, respectively. NK cells expressing anti-
CD19-BB-ζ secreted IFN-γ in response to CD19+ target cells
and had enhanced cytotoxicity against B-cell malignancies (100).
Transduced NK cells were consistently more cytotoxic than non-
transduced NK cells. A large-scale, GMP-compliant protocol was
also developed and showed that median percentage of geneti-
cally modified NK cells with receptor expression was 82% after
24 h. NK cells transfected under these conditions exerted in vivo
cytotoxicity in NSG mice with B-cell leukemia, and suppressed
leukemia progression compared withmice inoculated withmock-
transfected NK cells (100). Interestingly, NK cells can acquire
anti-CD19 CARs from donor cells via trogocytosis (101). When
co-cultured with live K562 cells transduced to express anti-CD19-
BB-ζ, NK cells acquired anti-CD19 CARs, peaking at 1 h and
declining thereafter. NK cells displayed enhanced degranulation
in response to leukemia cell lines compared with NK cells co-
cultured with control cells.
Genetically modified NK-cell lines, such as NK-92 cells, have
been tested for in vitro and in vivo efficacy against MM. IL-
2-independent derivatives of NK-92 cells, i.e., NK-92MI cells,
have been transduced with a first-generation CAR targeting
CD138, an integral membrane protein expressed on differen-
tiated plasma cells (102). Genetically modified NK-92MI cells
harbored a CAR consisting of an anti-CD138 single-chain vari-
able fragment (scFv) fused to CD3ζ chain. The retargeted NK
cells (NK-92MI-scFv) released IFN-γ and granzyme-B, and lysed
CD138-expressing MM cell lines. When assayed in a xenograft
NOD-SCID mouse model, transduced NK cells exerted more
potent anti-tumor activity toward CD138-expressing MM cells
than NK-92MI-mock. Importantly, NK cells could be detected in
theMMmicroenvironmentmore than 20 days after their adoptive
transfer.
CS1 is another surface protein highly expressed on MM cells
and is amenable to targeting with CS1-specific CARs (103). CS1
co-localizes with CD138 on polarized plasma cells where it pro-
motes adhesion, clonogenic growth, and tumorigenicity. Com-
pared with mock-transduced NK cells, CS1-CAR-transduced NK
cells had increased cytotoxic activity against CS1-expressing MM
cells and showed heightened IFN-γ production. In an orthotopic
MM xenograft model, adoptively transferred CS1-CAR-NK-92
cells suppressed the growth of human IM9 MM cells and sig-
nificantly prolonged mouse survival (103). Overall, studies with
CAR-NK cells point to the efficacy of this approach. The safety
profile of CAR-NK cells may be advantageous compared with that
of CAR-T cells, because of lack of in vivo clonal expansion and
cytokine storm. Also, CAR-NK cells should not induce GVHD,
while potently mediating GVL effects.
Natural killer cells can also be transduced to express mbIL-15
(104). Compared with NK cells expressing wild-type IL-15, mbIL-
15NK cells secreted low amounts of IL-15 in culture supernatants.
Membrane-bound IL-15 appeared to be mostly occupying
autologous receptors, suggesting that mb-IL-15 preferentially
stimulates cells in cis, i.e., by direct binding to receptors expressed
in the same cell. Genetically modified NK cells were maintained
and expanded in culture without exogenous IL-2. When tested
in vitro and in vivo, mbIL-15NK cells displayed enhanced survival
and cytotoxicity, being capable of inhibiting the growth of AML
and sarcoma cells in NOD-SCID IL-2Rγ-null mice.
A complementary approach to existing methods of genetic
modification of NK cells is offered by a retroviral vector-based,
gene transfer protocol (105). Using a SFα11GFP viral vector,
transduced NK cells were visible as GFP-expressing cells by flu-
orescence microscopy. The median transduction efficiency after
one or two rounds of transduction was 27 and 47%, respectively.
On day 21 of culture, transduction efficiencies averaged 52 and
75%, respectively. The gene transfer procedure did not affect NK-
cell phenotype or function, suggesting that retroviral vectors can
be successfully applied to immunotherapy trials.
Clinical experience with CAR-engineered NK cells is in its
infancy (106). Two clinical trials are currently open with the aim
at exploring the therapeutic benefit of haploidentical NK cells
modified with anti-CD19 CARs in children with B-cell precursor
ALL (ClinicalTrials.govNCT00995137) and in children and adults
with refractory ALL (ClinicalTrials.gov NCT01974479). In these
studies, NK cells will be expanded by co-culture with irradi-
ated K562 cells modified to express mbIL-15 and 41BB-ligand.
The expanded NK cells will be then transduced with a signaling
receptor that binds to CD19 (anti-CD19-BB-ζ).
Use of Expanded NK-Cell Lines
SeveralmalignantNK-cell lines have been established andused for
clinical trials in China, Japan, andWestern Countries, as reviewed
elsewhere (107). A potential drawback of this approach is that
differences in HLA molecules across different ethnicities may
translate into the production of HLA-specific antibodies by the
recipient. NK-92 cells, the most extensively characterized NK-cell
line, were established in 1994 from the PB of a male Caucasian
patient with non-Hodgkin lymphoma, are IL-2-dependent and
harbor a CD2+CD56+CD57+ phenotype (108–112). The adop-
tive transfer of NK-cell lines has theoretical advantages related
to lack of expression of inhibitory KIRs, lack of immunogenicity,
and ease of expansion. The optimal conditions for large-scale
ex vivo expansion of NK-92 cells were recently defined. The
protocol uses X-VIVO 10 serum-free media, supplemented with
450U/mL of pharmaceutical grade rhuIL-2, and 2.5% allogeneic
or autologous human serum or plasma (64). Cells maintained in
gas-permeable culture bag systems with regular addition of fresh
supplemented media achieve>200-fold expansion in 15–17 days,
from a starting population of 6.25 106 cells to approximately
1.5 109 total cells per 1 L-culture. Patients with solid tumors
or leukemia/lymphoma (n= 2) were treated with two infusions
of escalating doses of NK-92 cells given 48 h apart, with no
infusion-related or long-term side effects being observed (63).
NK-92 cell doses ranged from 1 109 to 1 1010 cells/m2. The
dose of 1010 cells/m2 was considered the maximum expandable
cell dose. NK-92 cells persisted in vivo for at least 48 h, as shown
by Y chromosome-specific PCR in two female patients. Some
responses were observed in patients with lung cancer. Only one
patient developed anti-HLA antibodies, despite the allogeneic
nature of NK-92 cells. NK-92 cells (Neukoplast®) will continue
to be tested in patients with solid tumors, e.g., Merkel cell
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cancer and renal cell carcinoma, and with hematological malig-
nancies1 (Table 1).
Since several decades, EBV-immortalized B-lymphoblastoid
cells (EBV-BLCL) are known to robustly support NK cell in vitro
expansion and anti-tumor activity (113–115). Escudier and col-
leagues used 35-Gy-irradiated LAZ 388 EBV-BLCL for the ex vivo
expansion of NK cells from patients with metastatic renal cell
adenocarcinoma. NK cells were initially cultured in V-bottom
microplates, at a 4:1 feeder cell to NK-cell ratio, in DMEM
medium supplemented with 200U/mL IL-2. Two to five days
before clinical use, NK cells were transferred to Baxter bags, where
they received an additional 250U/ml IL-2 boost. On average,
expansion of culturedNK cells was limited to 50-fold after 21 days.
However, some clinical responses were observed when autologous
NK cells were used as consolidation treatment for patients in
partial remission (116). Berg and co-workers described a GMP-
compliant protocol involving a 20:1 EBV-BLCL feeder to NK-
cell ratio and 500U/ml IL-2. This system allowed for a 300- to
930-fold NK-cell expansion. EBV-BLCL feeders prevalently drove
such an extensive phenomenon, as the use of PBMCs in similar
conditions yielded inferior results (69). Based on this protocol,
a phase I clinical trial is currently investigating technical fea-
sibility and clinical efficacy of large-scale NK infusions (up to
1 109/kg) in cancer patients receiving bortezomib administered
with the scope of increasing susceptibility of tumor cells to NK-
mediated lysis (117, 118).
K562 engineered to express mbIL-15 and 41BB-ligand (K562–
mb15–41BBL) may be used to efficiently propagate NK cells
with enhanced anti-leukemia properties. NK cells typically reach
a >20-fold expansion after 7 days of co-culture, and a >1,000-
fold expansion after 3weeks, with no concomitant T cell prop-
agation (67, 119). NK cells from patients with MM may also
efficiently growwhen co-culturedwithK562–mb15–41BBL (120).
When grown in GMP-compliant gas-permeable static cell culture
flasks (G-Rex), as many as 19 billion unmanipulated NK cells
can be obtained in 8–10 days starting from 150million NK cells
(93). Importantly, K562–mb15–41BBL cells have been success-
fully used to expand NK cells transduced with an anti-CD19-BB-
ζ CAR, which display enhanced reactivity to CD19+ leukemia
cells (119). Similar to K562–mb15–41BBL, K562 genetically mod-
ified to express mbIL-21, or to co-express the ligand for 41BB
and the NKG2D ligand MICA (K562–4-1BBL–mMICA), have
been shown to promote large-scale expansion of NK cells with
enhanced anti-tumor in vitro reactivity (121–123).
Impact of Expansion Methods on NK-Cell
Function and Homing Potential
There are theoretical concerns that extensive in vitro expan-
sion may affect the replicative potential and long-term viability
of in vivo-infused NK cells. For instance, both Fas expression
and susceptibility to apoptosis are increased after culture of NK
cells with IL-2 or with feeder cells (124). In addition, expanded
NK cells down-regulate receptors required for homing into sec-
ondary lymphoid organs, such as CCR7, a member of the G
1http://www.conkwest.com/nk-92
protein-coupled receptor family, and CD62L. In line with this,
NK cells expanded with genetically modified K562 cells were
shown to predominantly express a CD16+CD56+ phenotype,
with no detectable CCR7 (125). To obviate this, NK cells have been
cultured with genetically modified, IL-21/CCR7 expressing K562
cells. These culture conditions reportedly resulted into transfer of
CCR7 to 80%of expandedNK cells by trogocytosis, a fast, contact-
dependent uptake of membrane fragments, and molecules from
“donor” to “acceptor” cells (126). CCR7 conferred migratory
properties to NK cells by enhancing lymph node homing upon
adoptive transfer to athymic nude mice. NAM dose-dependently
increases CD62L expression on IL-2/IL-15-stimulated NK cells
(82). NK cells expanded with NAM displayed better in vitro
cytotoxic activity against a variety of tumor cell lines, including
leukemia cells, and enhanced homing, aswell as in vivopersistence
in NOD-SCID mice.
Recently, two GMP-grade NK cells products manufactured
at different production assistance for cellular therapies (PACT)
facilities were evaluated for homing characteristics, i.e., freshly
activated (FA)-NK, used by the Minnesota group, and ex vivo-
expanded (Ex)-NK, developed by the Baylor College of Medicine
group (93, 127). Although the two preparations had phenotypic
differences, cytotoxicity against NK-sensitive targets was simi-
lar. In vivo recovery after the infusion of thawed products was
lower compared with the infusion of fresh NK cells. Whereas
the negative impact of cryopreservation on FA-NK was rescued
by overnight culture with IL-2, this strategy was less effective on
Ex-NK cells, suggesting the need for optimized cell processing
methods (127). NK cells could be detected at day 7 but failed to
further expand between day 7 and day 14. Interestingly, higher
numbers of functional NK cells with enhanced expression of
NKG2A were recovered in mice infused with Ex-NK cells and
given IL-15. The homing pattern of the twoproductswas different,
with higher numbers of NK cells being detected in the BM ofmice
given Ex-NK cells and IL-15 compared with Ex-NK cells and IL-2.
Conversely, mice receiving FA-NK cells had more NK cells in the
spleen when given IL-15. This study emphasizes the importance
of continued cytokine stimulation for ex vivo-expanded cells,
and suggests that differences in the manufacturing process affect
in vivo homing and clinical efficacy of the NK-cell product.
Clinical Trials with NK Cells in
Hematological Malignancies
Autologous NK Cells
Early clinical studies exploited LAK-based immunotherapy in the
autologous setting. One hundred eight patients with refractory
metastatic cancer received LAK cells generated from autologous
PBMCs incubated with 1,000U/ml IL-2 for 3–4 days. Systemic
high-dose IL-2 was given to support LAK cells in vivo (128,
129). Objective tumor regression occurred in 22% of 106 evalu-
able patients. Median response duration was 10months for eight
patients achieving complete remission (CR). Further prospective
studies assessing the therapeutic effects of high-dose IL-2 and
LAK cells indicated a possible survival advantage for patients with
melanoma treated with LAK cells (130).
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Immunotherapy with systemic IL-2 and autologous LAK cells
was also given as consolidation treatment after autologous bone
marrow transplantation (BMT). Sixteen patients with lymphoma
received, 12–14 days post-transplantation, LAK cells generated
from PBMCs incubated with IL-2 for 5 days (131). In a similar
setting, NK cells obtained prior to transplant and activated with
IL-2 for 6 days were infused into 12 patients with advanced can-
cer and post-BMT pancytopenia (132). Concomitant with NK-
cell transfer, sequential high to low-dose systemic IL-2 was also
administered for over 90 days. This approach was well tolerated
and resulted in the early enhancement of NK-cell activity in four
recipients (132).
In general, trials with high-dose systemic IL-2 to support cir-
culating LAK or NK cells were limited by severe and potentially
lethal toxicities (e.g., vascular leak syndrome, oliguria, hypoten-
sion,myocardial infarction), counterbalancing the beneficial anti-
cancer effects of LAK activity (129, 131, 132). On the other
hand, chronic low-dose IL-2 treatment was relatively well toler-
ated (133–135), but unable to activate NK cells as robustly as
high-dose ex vivo IL-2, or IL-2 at concentrations that engage the
intermediate-affinity IL-2 receptor on NK cells (134, 136, 137).
Subsequent studies sought to maximize NK-mediated anti-tumor
effects. Ex vivo IL-2-activated NK-cell infusions were compared
with supplemental intravenous IL-2 boluses on days 28 and 35
during daily subcutaneous IL-2 administration in patients with
relapsed lymphoma or metastatic breast cancer. Both treatment
conditions induced strong NK-cell anti-tumor reactivity, and
boosted circulating cytokines, without any consistent impact on
clinical outcome compared withmatched patients from the Autol-
ogous Blood and Marrow Transplant Registry database (138).
The proliferation potential of NK cells isolated from cancer
patients may be similar to that of NK cells from healthy donors,
reassuring about the feasibility of manufacturing autologous NK-
cell products. Although autologous NK cells persist in vivo for at
least 1 week after infusion, they express lower levels of NKG2D, a
key activating receptor, and may necessitate in vitro re-activation
with IL-2 to lyse tumor targets (68).
Collectively, the analysis of phase II immunotherapy studies
with autologous NK cells failed to show efficacy (139). Several fac-
tors may have accounted for the disappointing results, including
competition with the recipient’s lymphocytes for cytokines and
“space”; inhibition of autologous NK cells by self-MHC (30, 140,
141); chronic immunosuppression induced by the tumor on host
immunity; and expansion of Treg cells by IL-2 (127). Autologous
NK cells are currently being tested in patients with hematological
malignancies and solid tumors (NCT00720785; Table 2) (142).
In this trial, which is recruiting participants, patients will receive
immune suppressive therapy with pentostatin, followed by
bortezomib to sensitize tumor cells to NK cytotoxicity (143),
escalating doses of autologous NK cells and IL-2.
Allogeneic NK Cells
Initial clinical trials on allogeneic T-cell depleted (TCD) hap-
loidentical HSCT for patients with AML showed enhanced NK-
mediated cytotoxicity when KIR-HLA class I mismatch occurred
(23). In 2005, Miller and co-workers administered haploidentical
NK cells in a non-transplantation setting to 43 patients with
advanced cancer. Three pharmacological regimens of different
intensity were used to prevent immunological rejection (57). After
a single leukapheresis, CD3+ T cells were depleted under GMP
conditions using CD3 microbeads. The TCD product was acti-
vated overnight with IL-2 before infusion. NK cells were enriched
to 40% on average after processing. The final IL-2-activated prod-
uct contained an NK-cell dose of 8.5 106 cells/kg of recipient’s
body weight and a final T-cell dose of 1.75 105 cells/kg. A low-
intensity immune suppressive regimen was administered on an
outpatient basis to the first 17 patients, followed by the infusion of
escalating doses ofNK cells. Importantly, no dose-limiting toxicity
occurred in this patient cohort. Using RT-PCR primers for donor-
specific MHC class I alleles, donor cells were shown to persist
for 5 days and to comprise <1% of circulating PBMCs, likely
due to immune rejection. Alternative low-intensity (fludarabine
alone) and high-intensity immune suppressive regimens (high-
dose cyclophosphamide and fludarabine) were subsequently used
in seven patients with renal cell carcinoma and 19 patients with
poor-prognosis AML, respectively. None of the patients given
fludarabine alone engrafted with donor NK cells. By contrast, 8 of
15 evaluable patients with AML showed at least 1% engraftment of
donor cells after NK-cell infusion. Overall, five patients achieved
a morphological CR. Among the four patients with a KIR-ligand
mismatch in the graft-versus-host direction, three achieved CR.
This was paralleled by the observation that CR was obtained only
in 2 of 15 patients without alloreactivity. Finally, IL-15 serum lev-
els were significantly higher in patients receiving higher-intensity,
lymphodepleting immune suppression, suggesting that a rise in
endogenous IL-15 may be required for the in vivo expansion and
persistence of infused NK cells.
Subsequent studies suggested the possibility that IL-2 admin-
istered after NK infusions also expands Treg cells, potentially
interfering with in vivo NK-cell proliferation (76). To address
this issue, IL-2 diphtheria toxin (IL-2DT) was administered to 15
patients with relapsed/refractory AML, 1 day before the enriched
NK product (145). IL-2DT is a recombinant cytotoxic fusion pro-
tein composed of the amino acid sequences for diphtheria toxin
followed by truncated amino acid sequences for IL-2. IL-2DT
reportedly depletes IL-2 receptor α-chain (CD25)-expressing
cells, including Treg cells. In this study, three processing methods
were used to prepare NK-cell products, including CD3 depletion
alone, CD3 depletion followed by CD56 selection, and single-step
CD3/CD19 depletion. Higher NK-cell doses were obtained after
depletion of CD3+ and CD19+ cells from a 5-h donor apheresis
collection. Among the 42 patients who did not receive host Treg
depletion, 21% achieved remissions. By contrast, Treg depletion
with IL-2DT resulted in remissions at day 28 for eight of 15
patients (53%). The magnitude of NK-cell expansion was also
higher after Treg depletion. The ability of IL-2DT to deplete Treg
cells was further supported by reductions in serum IL-35 concen-
trations 14 days after adoptive transfer. Finally, 7 out of 10 patients
(70%) with detectable donor NK cells attained CR by day 28
compared with only 1 of 5 patients (20%) lacking detectable donor
NK cells at day 7, suggesting that NK-cell persistence is required
for clinical efficacy. Interestingly, this study showed no correlation
between achievements of CR- and KIR-ligand mismatch.
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TABLE 2 | Completed and ongoing clinical trials with NK cells for patients with hematological malignancies are listed.
Pts. Diagnosis NK-cell preparation Status Clinical site Reference(s)/
NCI Identifier
10 Children with
MRD-negative AML
Conditioning with cyclophosphamide and
fludarabine; inhibitory KIR-HLA-mismatched
NK cells to reduce relapse risk; 6 doses of
1-million U/m2 IL-2 starting on day -1
Published St Jude Children’s Research
Hospital, Memphis, TN, USA
(59)
6 Leukemia, LY Immunotherapy with NK cells,
rituximab+GM-CSF; phase I
Completed (08/12) M.D. Anderson Cancer
Center, Houston, TX USA
NCT00383994
30 Lymphoma CD56 selection Published Duke University, NC, USA (144) NCT00586690
22 AML, MDS, JMML Haploidentical donor-derived NK cell infusion
and chemotherapy (CY, FLU, IL-2)
Completed (04/14) St Jude Children’s Research
Hospital, Memphis, TN, USA
NCT00640796
13 AL, LY, MY Allogeneic NK cells post-ABMT; phase I Completed (06/12) Tufts Medical Center, Boston,
MA, USA
NCT00660166
48 ALL, JMML, AML,
MDS, NHL
Haploidentical NK cells after chemotherapy
with clofarabine, CY, and etoposide; IL-2;
phase I
Completed (03/13) St Jude Children’s Research
Hospital, Memphis, TN, USA
NCT00697671
13 AML NK cells from haploidentical KIR-ligand
mismatched donors after FLU/CY
chemotherapy, followed by IL-2; phase I
Published Univ. of Bologna, Italy (75)
14 BCP-ALL Gene-modified NK cells; phase I Not recruiting St Jude Children’s Research
Hospital, Memphis, TN, USA
NCT00995137
86 Hematological
malignancies
NK cells after MRD or MUD HSCT in children
with solid tumors and leukemia; phase I
Recruiting NCI, Bethesda, MD, USA NCT01287104
13 Hematological
malignancies
NK cells and UCBT; phase I Recruiting M.D. Anderson Cancer
Center, Houston, TX, USA
NCT01619761
90 High-risk AML Donor NK cells and IL-2 before HSCT with
CD34+ cells and RIC; phase I/II
Active, not recruiting Masonic Cancer Center,
University of Minnesota
NCT00303667
6 CD20+ relapsed
NHL or CLL
Allogeneic NK cells; CY, FLU and rituximab
followed by IL-2; phase I/II
Published Masonic Cancer Center,
University of Minnesota
(76)
6 Relapsed NHL or
CLL
Donor NK cells, rituximab, IL-2 and
chemotherapy; phase I/II
Terminated early [failure to
meet primary outcome
(NK expansion)]
Masonic Cancer Center,
University of Minnesota
NCT00625729
47 Hematological
malignancies
Donor NK cells after haploidentical HSCT;
phase I/II
Completed (02/13) Asan Medical Center, Seoul,
Korea
NCT00823524
10 MM In vitro-expanded haploidentical NK cells;
phase I/II
Recruiting University Hospital, Basel,
Switzerland
NCT01040026
15 Hematological
malignancies (and
solid tumors)
Pre-emptive NK-DLI early after HSCT;
phase I/II
Active, not recruiting University Hospital, Basel,
Switzerland
NCT01386619
33 High-risk AML in CR,
not eligible for HSCT
CNDO-109-activated allogeneic NK cells;
phase I/II
Ongoing; preliminary
results (7 patients)
presented at 2014 ASH
Meeting
United States (multi-center) NCT01520558 and
ref. (77)
30 AL, MDS HLA-haploidentical NK cells following
salvage chemotherapy for patients who have
relapsed or persistent leukemia following
allogeneic HSCT; phase II
Ongoing, not recruiting Memorial Sloan-Kettering
Cancer Center, NY, USA
NCT00526292
2 Relapsed ALL Haploidentical NK cells+ epratuzumab and
low-dose IL-2; phase II
Terminated (slow accrual) M.D. Anderson Cancer
Center, Houston, TX, USA
NCT00941928
(145)
34 NHL, CLL Lymphodepleting chemotherapy with
rituximab and allogeneic NK cells; phase II
Recruiting Masonic Cancer Center,
University of Minnesota
NCT01181258
43 AML, MDS NK-cell-based non-myeloablative
haploidentical HSCT; phase II
Recruiting Masonic Cancer Center,
University of Minnesota
NCT01370213
6 CML NK cells and non-myeloablative HSCT;
phase II
Completed (11/14) M.D. Anderson Cancer
Center, Houston, TX, USA
NCT01390402
(Continued)
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 23011
Pittari et al. NK cells for hematological malignancies
TABLE 2 | Continued
Pts. Diagnosis NK-cell preparation Status Clinical site Reference(s)/
NCI Identifier
46 MDS Decitabine and vorinostat conditioning
followed NK cell infusion and IL-2; phase II
Recruiting Masonic Cancer Center,
University of Minnesota
NCT01593670
18 Refractory/relapsed
AML
Neukoplast™ (NK-92); 1-5109/m2;
phase I
Recruiting Conkwest, Inc. NCT00900809
15 Hematological
malignancies
Neukoplast™ (NK-92), 1-5109/m2;
relapse after autologous HSCT; phase I
Recruiting University Health Network,
Toronto
NCT00990717
16 AL, MDS NK cells and IL-2 before UCBT; phase II Terminated (competing
study started)
Masonic Cancer Center,
University of Minnesota
NCT00354172
18 LY or solid tumors Ex vivo-expanded allogeneic NK cells
(MG4101); phase I
Completed (03/13) Seoul National University
Hospital, Korea
NCT01212341
N.A. Hematological
malignancies, solid
tumors
Autologous NK cells 24h after treatment with
bortezomib; IL-2; phase I
Recruiting National Heart, Lung, and
Blood Institute, MD, USA
NCT00720785
AML, acute myeloid leukemia; MRD, minimal residual disease; ALL, acute lymphoblastic leukemia; LY, lymphoma; MY, multiple myeloma; JMML, juvenile myelomonocytic leukemia;
NHL, non-Hodgkin lymphoma; CY, cyclophosphamide; FLU, fludarabine; UCBT, umbilical cord blood transplantation; RIC, reduced intensity conditioning; MRD, matched related donor;
MUD, matched unrelated donor; NCI, National Cancer Institute; ASH, American Society of Hematology. *Clinical-grade CTV-1 lysate that primes NK cells ex vivo; see main text for
further details. N.A. , not available. www.clinicaltrials.gov website, last accessed March 2015.
Haploidentical, KIR-ligand-mismatched NK cells have been
safely infused in elderly patients with high-risk AML, with some
evidence of clinical benefit, especially for patients treated in CR
or for those with molecular disease relapse (75). Approximately,
40%of the screened patients had aKIR-ligand-mismatched donor,
suggesting that this strategy may be applicable to a signifi-
cant proportion of patients with AML. Another study attempted
to exploit KIR-ligand-mismatched NK cells from haploidentical
family donors in patients with relapsed MM (74). The apheresis
products were TCD and then cultured with IL-2, either overnight
or during incubation with anti-CD3 beads. Patients received
melphalan and fludarabine as conditioning regimen. After NK-
cell infusion, IL-15 levels increased. The response rate (RR)
was 50%, with no patient developing GVHD. However, donor
chimerismwas eventually lost in conjunction with the appearance
of host–anti-donor immune responses. The clinical application of
allogeneic NK cells to patients with MM is further encouraged
by the observation that most MM cell lines are susceptible to NK
attack in vitro, showing no evidence for HLA class I loss (146).
Resting human NK cells can be primed to kill NK-resistant
tumor cells by co-incubation with a clinical-grade lysate of the
leukemia cell line CTV-1 (CNDO-109). CNDO-109-activatedNK
cells remain primed, with no requirement for IL-2 treatment, and
can be cryopreserved. The safety, outcome and NK chimerism
data from an ongoing phase I/II transitional clinical trial of
CNDO-109-NK cells have been recently reported (77). This 3 3
dose-escalation phase 1 studywas opened in 2013 for patients with
high-risk AML in first CR and with no conventional treatment
options available. Patients received preparative chemotherapy
consisting of cyclophosphamide and fludarabine on study day-6
to -2, followed by a single dose of CNDO-109-activated NK cells
on day 0. Patients were given different doses of NK cells (cohort
1= 3 105, cohort 2= 1 106, and cohort 3= up to 3 106
cells/kg). CNDO-109-NK cells were manufactured from a single
apheresis collection fromHLA-haploidentical-related donors. NK
cells were isolated with anti-CD56 microbeads and co-incubated
overnight with CNDO-109 lysate under GMP conditions (Coro-
nado Biosciences)2. Residual T-cell contamination (defined as
<104 cells/kg patient body weight) was considered a safety cri-
terion for lot release. Seven eligible patients were enrolled. No
infusion-related toxicities or adverse events directly attributed to
NK therapy were observed, including GVHD. Patients experi-
enced transient myelosuppression lasting approximately 2weeks.
Three patients relapsed early post-treatment (average time to
relapse from CR1 being 104 days). In five of seven evaluable
patients, persistence of activated donor NK cells was observed
from day 7 post-infusion to as late as day 56 in one patient. The
comparison of donor and patient endogenous NK cells showed
a mature activated phenotype of donor NK cells. Two of the
three patients evaluated had persistence of low levels of activated
autologous NK cells (~10–20% of circulating NK cells), exceed-
ing the numbers circulating pre-treatment. This observation may
indicate that NK-cell therapy induces endogenous NK activation
and enhances innate immunity to AML in the absence of exoge-
nous cytokine administration. When the study was published in
abstract form, four of the seven patients enrolledwere relapse-free.
Natural killer cells have also been administered pre-emptively
to patients with high-risk cancer, after TCD haploidentical HSCT
(73). Sixteen patients were treated in a prospective phase II
study with purified NK cells on day 3, 40, and 100 after HSCT.
The median dose of NK cells was 12.1 106/kg. With a median
follow-up of approximately 6 years, 4 out of 16 patients were
alive. The four patients who developed acute GVHD had received
>0.5 105/kg contaminating T cells. Compared with a historical
cohort of patients treated with haploidentical HSCT without NK
donor lymphocyte infusions (DLIs), NK cells apparently exerted
no effect on disease relapse.
2http://www.coronadobiosciences.com/research-development/cndo-109.cfm
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Trials in Children and Young Adolescents
A landmark study from St. Jude Children’s Hospital (NKAML)
has shown the safety, feasibility, and engraftment potential of hap-
loidentical NK cells for children with favorable and intermediate-
risk AML (59). Patients received a mild conditioning regimen,
consisting of cyclophosphamide (60mg/kg on day-7) and flu-
darabine (25mg/m2/day from day-6 to -2), followed by KIR-
HLA-mismatched NK cells (median number of cells infused
29 106/kg) and six doses of IL-2 (1 106 U/m2). Donor PBMCs
obtained by leukapheresis were depleted of CD3+ T cells and then
enriched for CD56+ cells. The manipulated product contained a
very low number of contaminating B cells and T cells. The result-
ingNK population was infused fresh, without any incubationwith
IL-2.All patientswere inCR, as shownbyminimal residual disease
status. NK infusions werewell tolerated, with noGVHDobserved.
NK-cell engraftment was transient in all patients, with a median
peak NK-cell chimerism of 7%. One patient had prolonged NK
engraftment with 2% of donor NK cells being detected at day 189,
in association with delayed neutrophil and platelet engraftment.
With a median follow-up of approximately 32months, all patients
remained in remission. The 2-year EFS estimate was 100%.
The therapeutic potential of NK cells has also been tested in
young adolescents. A two-step T-cell depletion strategy with a
final CD56 enrichment step was pursued to isolate NK cells from
steady-state leukapheresis collections (147). Purified NK cells
were expanded for 2weeks inX-VIVO10mediumcontaining 10%
human AB serum and 1,000U/ml IL-2. This procedure resulted
in a median 95% NK-cell purity, 99% viability, and enhanced
cytotoxicity against the K562 line as well as primary leukemic
blasts obtained from patients. T-cell contamination was negligible
(<0.1%). Three childrenwithmultiply relapsedALL orAMLwere
treated with IL-2-stimulated NK cells after haploidentical HSCT.
Directed KIR mismatches in the GVL direction were present in
all three cases. Remission was achieved in all cases, although
patients ultimately died of infectious complications or disease
relapse. Another study in children and young adolescents with
ultra-high-risk solid tumors has shown that donor-derived NK
cells activated with IL-15 and 41BBL can be safely administered
after HLA-matched TCD HSCT (148). NK cells displayed potent
killing capacity. However, five of nine transplant recipients devel-
oped acute GVHD, with grade III GVHD being observed in three
patients. The unexpected occurrence of GVHD in this report
may be attributed to timing of NK-cell infusion, lack of post-
transplantation immune suppression or activation of NK cells that
were expanded on IL-15-secreting feeder cells (149). The obser-
vation that GVHD developed in all four patients given unrelated
donor transplants compared with one of five patients given related
donor transplants points to a T-cell-driven mechanism, mediated
by minor antigens and accentuated by the infused NK cells.
In vivo Targeting of NK Cells with Antibodies
IPH2101 is a first-in-class, non-depleting human IgG4 mAb
directed against inhibitory KIRs, and functions by blocking
inhibitory KIR–ligand interactions, leading to restored or aug-
mented NK-cell function against tumor cells. A phase I trial of
IPH2101 (#NCT00552396) was conducted in 32 patients with
relapsed/refractory MM (150). IPH2101 was given intravenously
every 28 days in sevn dose-escalated cohorts (0.0003–3mg/kg)
for up to four cycles. This study identified doses of IPH2101,
which conferred KIR2D occupancy in vivo, with no concomitant
dose-limiting toxicity or identification of a maximally tolerated
dose (MTD). With one exception, adverse events were mild and
transient and mainly consisted of self-limited infusion reactions.
Although IPH2101 enhanced ex vivo patient-derived NK-cell
cytotoxicity against MM, no objective responses were observed.
Another phase I study of escalating doses of IPH2101 in 23 elderly
patients with AML in first CR showed a correlation between
IPH2101 exposure andKIR occupancy (151). Adverse events were
mild and transient, consisting mainly of infusion syndrome and
erythema. The study drug did not affect the numbers and distri-
bution of lymphocyte subsets and NK cell receptor expression. At
the highest dose levels, TNF-α andMIP-1β serum concentrations,
as well as CD69 expression on NK cells, transiently increased.
Overall and relapse-free survival compared favorably to reports
in other patient populations with similar characteristics (151).
An immunization study of transgenic mice bearing human
immunoglobulin loci with different combinations of KIR2DLs
has recently led to the identification of the 1-7F9 mAb, based on
binding to soluble, recombinant KIR2DL1, -2, and -3 by ELISA
(152). The 1-7F9 antibodies bind to human NK cells, γδ+ T
cells, and CD8+ T cells, consistent with KIR expression patterns.
Using in vitro assays, 1-7F9 blocked the binding of HLA class I
to inhibitory KIR2DLs, augmenting NK cell-mediated killing of
HLA-C-expressing targets. 1-7F9 also enhanced the cytotoxicity
of NK cells from an HLA-C-matched donor against AML blasts.
Pre-treatment with 1-7F9 of patient-derived NK cells translated
into a two- to threefold increase in cytotoxicity against autol-
ogous AML cells. Finally, studies in NOD-SCID mice showed
that 1-7F9 potentiates NK-mediated killing and promotes mice
survival compared with co-infusions of NK cells and AML blasts
alone (152).
Bi-Specific and Tri-Specific Antibodies
A novel class of therapeutics uses either all or part of the antibody
structure to deliver enhanced effector activity to the tumor site.
The fusion of two (bi-specific) or three (tri-specific) portions
of the fragment of antigen-binding (Fab) region of a traditional
antibody yields reagents with high level of antigen specificity
and cross-links tumor antigens with potent immune effectors.
Bi-specific killer engagers (BiKEs) are constructed with a single-
chain Fv against CD16 and a single-chain Fv against a tumor-
associated antigen. The mechanisms by which BiKEs and TriKEs
potentiate NK effector functions include intracellular calcium
mobilization through direct CD16 signaling (153). Co-culture
of reagent-treated resting NK cells with Raji targets also trans-
lates into increased NK-cell degranulation, target cell death, and
NK production of IFN-γ, TNF-α, GM-CSF, IL-8, MIP-1α, and
RANTES.
Fully humanized CD16 33 BiKEs have been shown to trig-
ger NK-cell activation in vitro against CD33+ AML cell lines
and primary refractory CD33+ AML targets (154). Combina-
tion treatment with BiKEs and ADAM17 inhibitor to prevent
CD16 shedding further enhanced NK-cell function. BiKEs were
also effective at activating NK cells from recipients of double
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UCB transplantation. BiKEs enhance degranulation and cytokine
production by NK cells derived from patients with myelodys-
plastic syndromes and cultured with CD33+ AML cell lines,
irrespective of disease stage and age stratum (155). A poten-
tial drawback of this approach is the relatively short half-
life of the antibody constructs, with limited trafficking to the
tumor site.
Other Approaches to Target NK Cells In vivo
A first in-human trial of Escherichia coli-produced rhIL-15
has been recently published (156). The primary objectives of
this single-institution, open-label, non-randomized 3+ 3 design,
phase I dose-escalation study were to assess safety, dose-limiting
toxicity, and MTD of rhIL-15 given as intravenous bolus at
3.0, 1.0, and 0.3µg/kg/day for 12 consecutive days to patients
with metastatic malignant melanoma or renal cancer. Reduc-
tions in the number of lymphocyte subsets were evident within
20min of the infusion of IL-15, with the most dramatic decline
being observed with NK cells, γδ+ T cells and CD8+ mem-
ory T cells. The acute efflux of CD8+ cells from the circula-
tion was most pronounced for transitional and effector mem-
ory subsets. An influx of NK cells to the blood was detected
by 4 h, followed by a normalization of cell counts by 2–3 days.
The initial influx of cells mainly resulted from redistribution,
because no evidence of proliferation was observed until 48 h.
CD8+ cells showed evidence of activation, including prolifer-
ation and increased expression of CD38 and HLA-DR. Dose-
limiting toxicities in patients receiving 3.0 and 1.0µg/kg/day
included grade 3 hypotension, thrombocytopenia, and elevations
of ALT and AST, resulting in 0.3µg/kg per day being determined
the MTD. Common cytokine-related adverse events, including
fever, rigors, and hypotension occurred much less frequently in
patients treated with the 0.3µg/kg dose level. Cytokines such
as IFN-γ, TNF-α, IL-6, and IL-8 increased up to 50-fold in
patient serum after rhIL-15 administration. Overall, there were
no clinical responses in this study, with stable disease being
recorded as a best response. However, five patients manifested
a decrease between 10 and 30% in their marker lesions, with
two of these patients experiencing clearing of lung lesions (156).
This study proves that rhIL-15 administration, as an intravenous
bolus dose, is associated with clinical toxicities due to marked
cytokine secretion. The authors initiated a dose-escalation trial
of continuous intravenous infusion of rhIL-15 to patients with
metastatic malignancies. Furthermore, the Cancer Immunother-
apy Trials Network (CITN3) is conducting a phase I dose-
escalation trial of subcutaneous rhIL-15 administered 5 days per
week for 2weeks.
Current Manufacturing Practices for CIK
Cells
Current protocols to differentiate CIK cells are based on the
combination of 1,000 IU/ml IFN-γ on day 1 of culture followed
24 h later by 50 ng/ml OKT3 and 300 IU/ml IL-2 (157). After
21–28 days, CD3+CD56+ cells, derived from CD3+CD56  cells,
acquire cytotoxicity against various tumor cell targets, including
AML, chronicmyeloid leukemia, and B-cell and T-cell lymphoma.
The expression of CD56 on CIK cells is thought to result pri-
marily from IFN-γ priming with subsequent IL-12 production
from monocytes. Recently, a GMP-grade protocol (ITG2) that
incorporates thymoglobulin® (TG) was used to prepare CIK cells
(Figure 2; Table 3) (45). TG is a purified, pasteurized preparation
of polyclonal γ immunoglobulin raised in rabbits against human
thymocytes (45). TG expanded CIK cells more efficiently than the
3http://citninfo.org/citn-science/clinical-studies.html
FIGURE 2 | Protocols to generate CIK cells from PBMCs. (A) Current protocols used to differentiate CIK cells from PBMCs rely on IFN-γ, anti-CD3 mAbs or
thymoglobulin (TG), and IL-2. (B) A representative experiment depicts the phenotype of CIK cells after 3-week culture under the above cytokine conditions.
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TABLE 3 | Completed and ongoing clinical trials with CIK cells for hematological malignancies are listed.
Pts. Diagnosis CIK cell preparation Status Clinical site Reference(s)/
NCI Identifier
11 AML, HL, CML,
ALL, MDS
LK or PB; 1,000U/ml IFN-γ+OKT3+ IL-2 for 20–26d;
median number of total allogeneic CIK cells 2.4106/kg
(7.2–87.4); phase I
Published Italy (157)
5 AL UCB washout after UCB transplantation Published Italy (162)
9 DLBCL Autologous PB; 2,000U/ml IFN-γ+OKT3+ IL-2 Published China (163)
10 Lymphoma
(n=2)
1,000U/ml IFN-γ+OKT3+ IL-2; CIK cells then transfected
with pCEP-IL-2-plasmid
Published Germany (164)
1 Plasmocytoma Autologous CIK cells; monthly for 21 courses Published China (165)
12 Lymphoma
(n=6)
LK or PB; median 28109 (range, 6–61) CIK cells per
patient
Published Italy (166)
41 MDS/MPD Post-transplantation infusion of allogeneic CIK cells as
consolidation therapy; phase II
Recruiting Stanford
University, USA
NCT01392989
17 AML/MDS Autologous CIK cells after HSCT or in patients unfit for
standard curative chemotherapy; phase I/II
Completed Singapore
General Hospital
NCT00394381
11 CML Adoptive immunotherapy in patients receiving standard
drug therapy; phase II
Completed Singapore
General Hospital
NCT00815321
20 Hematological
malignancies
Allogeneic CIK cells as post-HSCT immunotherapy; phase I Active, not
recruiting
NIH, US NCT00185757
20 Hematological
malignancies
Allogeneic CIK cells for relapse after allogeneic HSCT;
phase I/II
Recruiting Singapore
General Hospital
NCT00460694
PBMC, peripheral blood mononuclear cells; AL, acute leukemia; DLBCL, diffuse large B-cell lymphoma; LK, leukapheresis; CML, chronic myeloid leukemia; MDS, Myelodysplastic
syndromes; MPD, myeloproliferative disorders; d, day; UCB, umbilical cord blood; SCGM, stem cell growth medium; MM, multiple myeloma. www.clinicaltrials.gov website last accessed
March 2015.
anti-CD3 mAb when provided to clinical-grade cultures in com-
bination with IFN-γ and IL-2. Higher levels of NKG2D, NKp46-
triggering receptor, and killer-like immunoglobulin receptors
KIR2DL1 and KIR2DL2/DL3 were detected on CIK cells dif-
ferentiated with TG compared with those obtained with αCD3
antibodies. CIK cells were capable of lysing tumor cell targets
in an MHC-unrestricted manner and released high quantities
of bioactive IL-12p40. The use of the ITG2 protocol was not
associatedwith the emergence of Treg cells in vitro, thus reassuring
against the infusion of excessive numbers of tumor-suppressive
T-cell populations.
The administration of bulk CIK cells is not associated with
GVHD in mice, even after sequential infusions (158). The same
study also showed that bulk CIK cells are more effective than
selected CD56+ CIK cells or CIK cells depleted of potentially
alloreactive αβ+ CIK cells.
Several investigators have successfully obtained CIK cells from
UCB units. The washouts of UCB units may yield approxi-
mately 500 106 CIK cells after a standardized 21-day expan-
sion culture (159). Compared with PB-derived CIK cells, UCB
CIK cells demonstrate lower immunogenicity and higher pro-
liferative capacity and anti-tumor activity in pre-clinical models
of cancer (160). Interestingly, UCB-derived CIK cells released
higher amounts of IL-2 and IFN-γ and expressed higher lev-
els of CCR6 and CCR7, pointing to a better ability to traffic
to tumor sites and secondary lymphoid organs. CIK cells dif-
ferentiated from PB and UCB also differ in receptor expres-
sion and in cytotoxic activity against ALL cells, suggest-
ing that the source of CIK cells may impact on therapeutic
efficacy (161).
Clinical Trials with CIK Cells
An International Registry on CIK Cells (IRCC) has been estab-
lishedwith the aimof reporting results fromclinical trials centered
on adoptively transferred CIK cells. In the first IRCC publication
(167), eleven clinical trials with autologous or allogeneic CIK cells
were identified, with 426 patients enrolled. Most trials included
male patients with hepatocellular carcinoma, gastric cancer, and
relapsed lymphoma. A clinical response was reported in 384
patients, who received up to 40 infusions of CIK cells. The total RR
was 24% and a decrease of tumor volumewas documented in three
patients. DFS rates were significantly higher in patients treated
with CIK cells than in a control group without CIK treatment. An
update published in 2014 (168) enlists the results obtained in 2,729
patients from 45 phase I/II studies. A total of 1,520 patients with
22 different tumor entities were treatedwithCIK cells, either alone
or in combination with chemotherapy. Allogeneic CIK cells were
employed in the majority of the trials (41 out of 45). The number
of CIK cells infused varied among the different trials, averaging
7.7 109 cells. Data on patient survival were available for 19 out
of 45 trials; 15 of these 19 trials were paired, as they also included
control patients receiving none or standard therapy alone. Overall,
a beneficial effect of CIK cells emerged in patients with hepatocel-
lular carcinoma, renal cell carcinoma, non-small cell lung cancer
(NSCLC), colorectal carcinoma, and breast cancer. High numbers
of CIK cells at time of infusion were associated with a better
prognosis. Quality of life was also improved in four of the five
trials for which data were disclosed. Ancillary biological data were
provided in 23 studies. The absolute numbers of T cells, as well
as serum IFN-γ, were increased after immunotherapy compared
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with baseline. Some studies also reported a decrease of blood
Treg cells after CIK infusions. Immunotherapy was generally well
tolerated, with fever occurring in 41% of cases and headache and
fatigue reported in 30% of cases (168). Mild GVHD was observed
in seven of 52 patients treated with allogeneic CIK cells and was
responsive to steroid therapy. Based on these findings, the IRCC
currently recommends the use of at least 10 109 CIK cells with
at least 30% CD3+CD56+ cells per infusion, every 2–4weeks, for
at least six times. The IRCC website4 (last accessed March 2015)
lists 1,787 patients treatedwithCIK cells,mostly for hepatocellular
carcinoma, gastric cancer, ovarian cancer, renal cell cancer, MM,
and NSCLC.
China has the largest population of patients with malignant
tumors and is the country where most clinical trials with CIK
cells were conducted (169). Using the VIP database of Chinese
scientific and technological journals5, 24 articles were selected.
Information on the total number of CIK cells used was avail-
able in 16 studies and ranged from 6 106 to 1.5 1010 in one
single treatment course. As far as hematological malignancies
are concerned, 1 study specifically dealt with non-Hodgkin’s dis-
ease (12 patients) and 4 studies with AML (51 patients). Only
14 out of 24 studies contained details about clinical outcome.
Of the reported 563 patients, 40 had a CR, 126 had a partial
response, 125 had a minimal response, 135 had stable disease,
and 58 had progressive disease. The remaining 76 patients did
not reach an objective response. The overall RR was 51.7%
(291/563) (169). Information on patient outcome was provided
in 10 studies. Four studies reported a 1-year OS rate of 72.5%,
six studies reported 2-year OS rate of 66.3%, one study reported
3-year overall RR of 75.5%, and two studies reported 5-year OS
rate of 38.2%.
A phase I study of allogeneic CIK cells has been conducted
in 11 patients with hematological malignancies relapsing after
allogeneic HSCT (157). Six patients had received other salvage
treatments before CIK administration, including DLIs, without
significant clinical response. The median number of CIK cells
infused was 12.4 106/kg, with no infusion-related toxicities
recorded. Acute GVHD occurred in four patients 30 days after
the last CIK infusion, and progressed into extensive chronic
GVHD in two cases. Disease progression and deathwere observed
in six patients. One patient had stable disease, one experi-
enced hematologic improvement, and three obtained complete
responses. The same authors differentiated CIK cells from UCB
samples and administered them to five patients relapsed after
UCB transplantation (162). In three patients, chemotherapy had
been given before CIK administration to reduce disease burden.
Infusions of a median of 1.5 106/kg CIK cells were provided
early after leukemia relapse. Some clinical response was observed
in one patient who also developed acute intestinal GVHD. The
remaining four patients experienced disease progression and died.
GVHDwasmanagedwith steroids andmesenchymal stromal cells
but the patient ultimately succumbed to leukemia relapse (162).
In another study (170), CIK cells were generated for 24 patients
with advanced-stage hematological malignancies, mostly from
4http://www.cik-info.org/index.php?kat=tableclinicaltrials
5http://oldweb.cqvip.com
allogeneic donors, either under steady-state conditions or after
stem cell mobilization. Overall, 55 infusions were given to 16
patients at doses ranging from 10 to 200 106 CD3+ cells/kg.
Notably, the proportion of the CD3+CD56+ subset was higher
in CIK cultures derived from patients than in those differen-
tiated from healthy donors. The median expansion of CD3+
T cells and CD3+CD56+ NK-like T-cells was 9.33-fold and
27.77-fold, respectively. Responses attributable to CIK infusions
were documented in five patients, including two with ALL, two
with Hodgkin disease, and one with AML. In five patients, the
response to CIK cells could not be assessed as salvage chemother-
apy or dasatinib was concomitantly administered. Acute GVHD
occurred in three patients and was manageable. For three of
the six patients failing to respond, leukemia cells were avail-
able for in vitro killing assays, which showed only modest cyto-
toxicity of donor CIK cells against tumor targets. Overall, this
study in advanced-stage hematological malignancies suggests
that CIK administration may translate into some clinical effi-
cacy with a modest toxicity and low incidence and severity
of GVHD.
Finally, autologous immune effector cells generated by TG,
IFN-γ, and IL-2 (ITG2) can be safely administered to patients with
advanced and/or refractory solid tumors (Figure 2) (171). After
2–3weeks in culture, a median of 4.65 106 immune effectors/kg
of recipient’s body weight was infused intravenously without
observing any toxicity. One patient with advancedmelanoma died
because of disease progression before the infusion of CIK cells.
The target dose of at least 2.5 106 CIK cells/kg of recipient’s
body weight was reached in four out of five evaluable patients.
The median survival was 4.5months (range 1–13) from the first
infusion of CIK cells (171).
Closing Remarks
Although the field of NK cell and CIK cell-based immunotherapy
is rapidly advancing, some pre-clinical and clinical issues need
to be clarified before this immunotherapy approach is widely
offered to patients with hematological malignancies and solid
tumors (172).
Cell therapy products enriched for NK cells using CD3
depletion and CD56 selection contain variable percentages of
monocytes. It is now established that both monocytes and
monocyte-derived DCs can support NK-cell proliferation and
function (173). This implies that different NK-cell manufacturing
protocols may affect the cellular composition of the final prod-
ucts and impact on NK-cell function. Also, the optimal number
of NK cells to be infused remains to be determined. Patients
reportedly tolerate target doses of 2 107 NK cells/kg without any
serious side effect (78). This number of NK cells can be routinely
obtained from a 1-day large-volume leukapheresis. However, it
is possible that higher doses and/or multiple infusions of NK
cells may be required for optimal clinical efficacy. Whether NK
cells may exert their beneficial effects pre-emptively in patients
with disease remission, or rather in the context of HSCT warrants
particular attention (73). In this respect, KIR ligand mismatch
is expected to mediate a more powerful effect in T-cell-depleted
HSCT, since alloreactive T cells reportedly blunt NK reactivity
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(37, 174). Finally, recent discoveries on NK-mediated allorecog-
nition will guide the choice of the optimal NK-cell donor in
order to maximally exploit the anti-tumor effect (33). The iso-
lation of single KIR+ NK cells under GMP conditions is feasi-
ble and yields clinically applicable numbers of alloreactive NK
cells (65).
Current clinical evidence also points toCIK cells as a potentially
useful immunotherapy approach for cancer patients. Similar to
other forms of immunotherapy, the infusion of CIK cells may
be more efficacious at disease stages where the tumor burden is
relatively low or in an adjuvant setting, rather than for advanced
disease (175).
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